| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | GLAUKOS CORP | 3,136,232 | 77,581,337 | 45.39% | ||
| 2 | FIVE PRIME THERAPEUTICS INC | 1,092,152 | 45,324,308 | 26.52% | ||
| 3 | OCULAR THERAPEUTIX INC | 2,215,384 | 20,758,148 | 12.15% | ||
| 4 | CLOVIS ONCOLOGY INC | 407,416 | 14,259,560 | 8.34% | ||
| 5 | ACHAOGEN INC COM | 1,281,152 | 7,353,812 | 4.30% | ||
| 6 | Biotie Therapies Corp. | 268,672 | 3,855,443 | 2.26% | ||
| 7 | CymaBay Therapeutics | 1,048,601 | 1,772,135 | 1.04% |
Portfolio data is normalized using SEC Form 13F filings, including the Restatement filing (0001104659-16-118185, filed 2016.05.05).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
